The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell ...

MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

(SMMT) stock rises as its lung cancer drug ivonescimab with chemotherapy hit the main goal in a Phase 3 trial for lung cancer ...

Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell ...

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...